Page 47 - IJB-9-6

International Journal of Bioprinting Transdermal delivery of printed cisplatin

https://doi.org/10.1038/s41698-021-00199-8 51. Bhatnagar S, Kumari P, Pattarabhiran SP, et al., 2018, Zein
microneedles for localized delivery of chemotherapeutic
42. Zhou Z, Ding Z, Yuan J, et al., 2022, Homologous
recombination deficiency (HRD) can predict the therapeutic agents to treat breast cancer: Drug loading, release behavior,
outcomes of immuno-neoadjuvant therapy in NSCLC and skin permeation studies. AAPS PharmSciTech, 19(4):
patients. J Hematol Oncol, 15(1): 62. 1818–1826.
https://doi.org/10.1208/s12249-018-1004-5
https://doi.org/10.1186/s13045-022-01283-7
43. Wu S, Zhang Y, Zhang Y, et al., 2022, Mutational landscape 52. Infante JR, Benhadji KA, Dy GK, et al., 2015, Phase 1b
of homologous recombination-related genes in small-cell study of the oral gemcitabine ‘Pro-drug’ LY2334737 in
lung cancer. Cancer Med, 12(4): 4486–4495. combination with capecitabine in patients with advanced
solid tumors. Invest New Drugs, 33(2): 432–439.
https://doi.org/10.1002/cam4.5148
https://doi.org/10.1007/s10637-015-0207-9
44. Chang Q, Ornatsky OI, Koch CJ, et al., 2015, Single-cell
measurement of the uptake, intratumoral distribution 53. Rose M, Burgess JT, O’Byrne K, et al., 2020, PARP inhibitors:
and cell cycle effects of cisplatin using mass cytometry. Clinical relevance, mechanisms of action and tumor
Int J Cancer, 136(5): 1202–1209. resistance. Front Cell Dev Biol, 8(September): 564601.
https://doi.org/10.1002/ijc.29074 https://doi.org/10.3389/fcell.2020.564601
45. Skavatsou E, Semitekolou M, Morianos I, et al., 2021, 54. Brown TJ, Reiss KA, 2021, PARP inhibitors in pancreatic
Immunotherapy combined with metronomic dosing: An cancer. Cancer J, 27(6): 465–475.
effective approach for the treatment of NSCLC. Cancers https://doi.org/10.1097/PPO.0000000000000554
(Basel), 13(8).
55. Beatson EL, Chau CH, Price DK, et al., 2022, PARP inhibitors
https://doi.org/10.3390/cancers13081901 on the move in prostate cancer: Spotlight on Niraparib &
46. Ameri M, Kadkhodayan M, Nguyen J, et al., 2014, Human update on PARP inhibitor combination trials. Am J Clin Exp
growth hormone delivery with a microneedle transdermal Urol, 10(4): 252–257.
system: Preclinical formulation, stability, delivery and PK of 56. van der Wiel AMA, Schuitmaker L, Cong Y, et al., 2022,
therapeutically relevant doses. Pharmaceutics, 6(2): 220–234. Homologous recombination deficiency scar: Mutations
https://doi.org/10.3390/pharmaceutics6020220 and beyond-implications for precision oncology. Cancers
(Basel), 14(17).
47. Chen X, Prow TW, Crichton ML, et al., 2009, Dry-coated
microprojection array patches for targeted delivery of https://doi.org/10.3390/cancers14174157
immunotherapeutics to the skin. J Control Release, 139(3): 57. Frankenberg-Schwager M, Kirchermeier D, Greif G,
212–220.
et al., 2005, Cisplatin-mediated DNA double-strand
https://doi.org/10.1016/j.jconrel.2009.06.029 breaks in replicating but not in quiescent cells of the yeast
48. Vrdoljak A, McGrath MG, Carey JB, et al., 2012, Coated Saccharomyces cerevisiae. Toxicology, 212(2–3): 175–184.
microneedle arrays for transcutaneous delivery of live virus https://doi.org/10.1016/j.tox.2005.04.015
vaccines. J Control Release, 159(1): 34–42.
58. Schierl R, Rohrer B, Hohnloser J, 1995, Long-term
https://doi.org/10.1016/j.jconrel.2011.12.026 platinum excretion in patients treated with cisplatin. Cancer
49. Gill HS, Prausnitz MR, 2007, Coating formulations for Chemother Pharmacol, 36(1): 75–78.
microneedles. Pharm Res, 24(7): 1369–1380. https://doi.org/10.1007/BF00685736
https://doi.org/10.1007/s11095-007-9286-4
50. Ingrole RSJ, Gill HS, 2019, Microneedle coating methods:
A review with a perspective. J Pharmacol Exp Ther, 370(3):
555–569.
https://doi.org/10.1124/jpet.119.258707

Volume 9 Issue 6 (2023) 39 https://doi.org/10.36922/ijb.0048